PAPOTTI, Mauro Giulio
 Distribuzione geografica
Continente #
NA - Nord America 24.701
EU - Europa 16.960
AS - Asia 8.214
SA - Sud America 613
OC - Oceania 264
AF - Africa 241
Continente sconosciuto - Info sul continente non disponibili 32
Totale 51.025
Nazione #
US - Stati Uniti d'America 23.912
CN - Cina 4.535
IT - Italia 3.747
IE - Irlanda 1.972
DE - Germania 1.759
FR - Francia 1.508
SE - Svezia 1.498
UA - Ucraina 1.266
GB - Regno Unito 1.001
FI - Finlandia 974
KR - Corea 921
CA - Canada 637
JP - Giappone 613
AT - Austria 604
PL - Polonia 593
IN - India 573
VN - Vietnam 449
ES - Italia 352
BR - Brasile 345
BE - Belgio 307
TR - Turchia 304
NL - Olanda 282
AU - Australia 237
DK - Danimarca 213
RU - Federazione Russa 153
GR - Grecia 135
MX - Messico 132
HK - Hong Kong 128
TW - Taiwan 118
CH - Svizzera 115
AR - Argentina 105
SG - Singapore 99
RO - Romania 97
PT - Portogallo 96
SN - Senegal 85
CO - Colombia 64
IL - Israele 58
CZ - Repubblica Ceca 53
ID - Indonesia 51
SA - Arabia Saudita 50
NO - Norvegia 49
CL - Cile 48
PH - Filippine 46
PK - Pakistan 43
HU - Ungheria 42
MY - Malesia 39
TH - Thailandia 39
EG - Egitto 34
EU - Europa 31
UZ - Uzbekistan 31
HR - Croazia 29
ZA - Sudafrica 28
DZ - Algeria 27
RS - Serbia 27
NZ - Nuova Zelanda 26
IR - Iran 25
SI - Slovenia 23
AE - Emirati Arabi Uniti 20
EC - Ecuador 17
SK - Slovacchia (Repubblica Slovacca) 17
PE - Perù 15
MU - Mauritius 13
NG - Nigeria 13
VE - Venezuela 13
BG - Bulgaria 11
MA - Marocco 11
AM - Armenia 10
IQ - Iraq 9
BY - Bielorussia 8
JO - Giordania 8
MK - Macedonia 8
TN - Tunisia 8
GT - Guatemala 6
KZ - Kazakistan 6
BA - Bosnia-Erzegovina 5
PR - Porto Rico 5
SC - Seychelles 5
SD - Sudan 5
CY - Cipro 4
LB - Libano 4
LU - Lussemburgo 4
OM - Oman 4
PY - Paraguay 4
QA - Qatar 4
SY - Repubblica araba siriana 4
BD - Bangladesh 3
GE - Georgia 3
KE - Kenya 3
KW - Kuwait 3
LK - Sri Lanka 3
PA - Panama 3
CU - Cuba 2
LV - Lettonia 2
MT - Malta 2
RE - Reunion 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BO - Bolivia 1
BS - Bahamas 1
Totale 51.000
Città #
Chandler 2.652
Beijing 2.551
Dublin 1.938
Houston 1.746
Fairfield 1.451
Ann Arbor 1.100
Ashburn 1.013
Torino 930
Wilmington 873
Jacksonville 823
Redwood City 800
Villeurbanne 751
Woodbridge 747
Seattle 617
Medford 599
Princeton 580
Vienna 570
Nyköping 518
Cambridge 517
Dearborn 491
Warsaw 476
Pisa 423
Fremont 327
Milan 288
Boston 282
Shanghai 233
Dong Ket 229
Brussels 221
New York 211
Boardman 191
Turin 180
Guangzhou 171
Toronto 168
Nanjing 165
Tokyo 164
Verona 144
Hangzhou 135
Munich 118
Seoul 108
Norwalk 105
Pune 102
San Diego 99
Chicago 98
Rome 94
Düsseldorf 93
Montréal 90
Washington 84
Chengdu 80
London 80
Tappahannock 79
Falls Church 74
Madrid 70
Hefei 67
Lachine 67
Zhengzhou 67
Phoenix 66
Würzburg 66
Taipei 64
Wuhan 64
Mcallen 63
Paris 63
São Paulo 63
Bologna 62
Mountain View 62
Shenyang 62
Helsinki 60
Ottawa 57
Jinan 56
Pittsburgh 54
Silver Spring 53
Kunming 52
Rochester 51
Istanbul 49
Ankara 48
Buenos Aires 47
Central District 47
Changsha 45
New Delhi 44
Philadelphia 44
Hebei 42
Dallas 41
Santiago 41
Bethesda 40
Athens 39
Birmingham 39
Barcelona 38
Canberra 38
Amsterdam 37
Padova 37
Honolulu 35
Los Angeles 35
Moscow 35
Upper Marlboro 35
Chongqing 34
Lexington 34
Nanchang 34
Piemonte 34
Florence 33
Delhi 30
Detroit 30
Totale 28.953
Nome #
The weiss score and beyond--histopathology for adrenocortical carcinoma. 1.361
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. 997
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma 993
Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology 852
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. 739
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma 625
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 619
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? 570
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. 484
Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied 449
Morgana acts as an oncosuppressor in chronic myeloid leukemia. 422
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer 402
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. 400
Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. 397
Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients 386
Eccrine spiradenoma of the nipple: Case report, differential diagnosis and literature review 386
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart 366
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. 354
Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. 353
Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas 346
The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index - Which is the best predictor of prostate cancer after a negative biopsy? 332
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact 320
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 313
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors 310
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines 307
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 301
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer 294
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 294
Mesothelioma families without inheritance of a BAP1 predisposing mutation 292
Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia 288
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 285
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 282
Core biopsies of renal masses: a safe and accurate tool for managing all that is indeterminate 281
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 280
An international Ki67 reproducibility study in adrenal cortical Carcinoma 272
Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. 261
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 260
Pathology of the Adrenal Cortex: a Reappraisal of the Past 25 Years Focusing on Adrenal Cortical Tumors. 256
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. 254
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. 244
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates 242
Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours 240
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 239
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 237
Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. 233
Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis 229
Adjuvant mitotane treatment for adrenocortical carcinoma 225
Morgana is a new oncosuppressor in CML 223
MEN1 Gene Mutation and Reduced Expression Are Associated with Poor Prognosis in Pulmonary Carcinoids 222
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. 219
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 219
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 218
Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis 215
Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats. 202
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy 201
ELOVL5 Mutations Cause Spinocerebellar Ataxia 38 199
YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study 197
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 195
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up 194
Differentiation-inducing factor 1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and Thymidylate Synthase mRNAs accumulation 186
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 186
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 185
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma 185
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines 182
Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation 182
mTORC1 Complex is Significantly Over-Activated in SDHX-Mutated Paragangliomas 178
Distinctive pathological and clinical features of lung carcinoids with high proliferation index 177
H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features data from a multi-institutional series 174
Impact of COVID-19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy 173
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 171
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen 170
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study 166
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 166
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. 165
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 162
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 161
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 159
Utilility of flow cytometry as ancillary study to improve the cytologic diagnosis of thyroid lymphomas 158
CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype 157
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters 155
ACYLATED AND UNACYLATED GHRELIN PROMOTE PROLIFERATION AND INHIBIT SERUM STARVATION- AND CYTOKINE-INDUCED APOPTOSIS OF PANCREATIC BETA-CELLS AND HUMAN ISLETS. INVOLVEMENT OF cAMP/PKA, ERK1/2 AND PI3K/AKT SIGNALING 154
Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. 152
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas 152
Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal 144
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. 141
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme. 140
Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract 138
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. 134
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T) 133
Classification of pulmonary neuroendocrine tumors: New insights 132
mTOR/p70S6K in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. 130
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 127
Current state-of-the-art therapy for advanced squamous cell lung cancer 127
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 126
Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid Carcinoma, a deadly subtype of lung cancer 126
Thymidylate synthase expression in large cell carcinoma ofthe lung 123
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer 122
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid 121
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 120
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma 118
Totale 27.634
Categoria #
all - tutte 124.682
article - articoli 0
book - libri 0
conference - conferenze 8.867
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.549


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.412 0 0 0 0 0 0 0 728 337 540 1.214 593
2019/20208.900 451 445 595 949 750 1.444 1.004 655 858 714 617 418
2020/20216.706 579 455 589 390 593 496 609 378 672 629 493 823
2021/20226.649 337 377 374 477 359 350 482 413 289 472 1.339 1.380
2022/20239.336 929 633 228 889 863 2.275 817 595 999 262 482 364
2023/20243.498 614 801 353 288 373 593 209 267 0 0 0 0
Totale 52.899